메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing

TOKYO, Oct. 7, 2025 -- Celaid Therapeutics Inc. ("Celaid"), today announced the successful completion of the 1st Close of its Series B financing round, raising JPY 1.055 billion (USD 7.2 million) from venture capital firms and the Japan Agency for Medical Research and Development (AMED). Including grants and subsidies, Celaid's cumulative funding has reached JPY 2.52 billion (USD 17.14 million). This financing reflects recognition of the progress in the company's lead pipeline program CLD-001, a novel ex vivo-expanded hematopoietic stem cell (HSC) therapy for severe pediatric
- 김갑성 기자
- 2025-10-07 21:00
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

SYDNEY, Oct. 7, 2025 -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Berghofer for a first-in-class PD-L1 degrader program. The lead optimized compound, NDL2, is an advanced PD-L1 protein degrader currently in development and represents a new and innovative frontier of cancer immunotherapy. About PD-L1 Degradation and NDL2 Cancer cells frequently express PD-L1 protein to evade immune attack. When PD-L1 on a tumor cell surface bin
- 김갑성 기자
- 2025-10-07 20:30
Pantai Hospital Kuala Lumpur at Kuala Lumpur Standard Chartered Marathon 2025

[ 메디채널 김갑성 기자 ] From preventive screenings to Medic-On-The-Run, Pantai Hospital Kuala Lumpur brings healthcare beyond the hospital for Generation after Generation. KUALA LUMPUR, Malaysia, Oct. 7, 2025 -- Health, like running, is a journey, not a destination. As Malaysia's runners pushed their limits at the Kuala Lumpur Standard Chartered Marathon (KLSCM) 2025, Pantai Hospital Kuala Lumpur (PHKL) ran with them, not just as medical support, but as a legacy partner in wellness, carrying its mission of care from one generation to the next. This year, a record-breaking 42,000 participants
- 김갑성 기자
- 2025-10-07 17:19
Milliken & Company Launches Millad ClearX™ 9000: The Clear Choice for Polypropylene

Delivers exceptional clarity with lower additive levels, streamlining production and expanding formulation options for converters and resin producers SPARTANBURG, S.C., Oct. 7, 2025 -- Milliken & Company proudly announces the launch of Millad ClearX™ 9000, the next generation clarifying technology for polypropylene (PP) developed to deliver ultra-clear transparency at reduced additive loading levels. Ideal for food packaging, home storage, and medical applications, Millad ClearX™ 9000 sets a new standard for value, aesthetics, and operational efficiency in transparent PP ap
- 김갑성 기자
- 2025-10-07 13:48
Kadisco General Hospital and MindHYVE.ai™ Sign Strategic MoU to Transform Healthcare in Ethiopia with Agentic AI

ADDIS ABABA, Ethiopia, Oct. 7, 2025 -- Kadisco General Hospital (KGH), one of Ethiopia's leading private healthcare institutions, and MindHYVE.ai™, a U.S.-based pioneer in agentic artificial intelligence (AI), have signed a Memorandum of Understanding (MoU) to launch an ambitious collaboration that will accelerate AI-powered healthcare innovation, operational efficiency, and workforce capacity-building in Ethiopia. The partnership, formalized in Addis Ababa on September 11, 2025, brings together Kadisco's strong foundation in clinical excellence with MindHYVE.ai's™ adva
- 김갑성 기자
- 2025-10-07 13:33
Terumo Blood and Cell Technologies Honored with Corporate Excellence Award at the Asia Pacific Enterprise Awards 2025 Regional Edition

SINGAPORE, Oct. 7, 2025 -- Terumo Blood and Cell Technologies (Terumo BCT) has been recognized with the Corporate Excellence Award at the Asia Pacific Enterprise Awards (APEA) 2025 Regional Edition organized by Enterprise Asia, a testament to its unwavering commitment to innovation, patient care, and global healthcare advancement. Serving customers in more than 160 countries, Terumo BCT empowers blood and cell-based therapies that improve patient outcomes and address unmet medical needs. With 7,900 associates and over 400 distributors, the company maintains a strong global presence spa
- 김갑성 기자
- 2025-10-07 13:25
Japanese Innovation Comes to Thailand: Revolutionary Myopia Management Device Kubota Glass Debuts at ASEAN International Optics Fair Bangkok 2025

TOKYO, Oct. 7, 2025 -- Leading Japanese pharmaceutical company Kubota Pharmaceutical Holdings Co., Ltd. will introduce Thailand to its groundbreaking myopia management device, Kubota Glass, at Bangkok. Addressing Thailand's Growing Myopia Crisis Thailand is facing a growing myopia challenge, with studies reporting that over 60%* of young adults are already myopic—among the highest rates observed in Southeast Asia. This pattern reflects the wider regional concern, where nearly half of the world's population is projected to be myopic by 2050. "Thai families are
- 김갑성 기자
- 2025-10-07 11:00
Revolutionary Myopia Management Technology Expands Across Asia -- Kubota Glass Makes Global Debut at ASEAN International Optics Fair Bangkok 2025

TOKYO, Oct. 7, 2025 -- Kubota Pharmaceutical Holdings Co., Ltd. (TSE: 4596) today announced that its groundbreaking myopia management device, Kubota Glass, will make its international debut at ASEAN International Optics Fair Bangkok 2025, taking place in Bangkok, Thailand, from October 9-11, 2025. Addressing Asia's Myopia Crisis With half of the world's population projected to become myopic by 2050, childhood myopia progression has emerged as a critical public health challenge, particularly across Asia where prevalence rates are among the highest globally. Current treatm
- 김갑성 기자
- 2025-10-07 10:00
Chula's "Smart Salt" Wins Gold for Cutting Sodium Without Losing Flavor

BANGKOK, Oct. 7, 2025 -- "Smart Salt," an innovative low-sodium salt developed by Paul Patsapong Chomchey, a Ph.D. candidate at Chulalongkorn University and Executive MBA alumnus, has won a Gold Medal and Special Award at the 2025 Silicon Valley International Invention Festival. Using Nano Chitosan technology, Smart Salt cuts sodium by more than half while preserving full flavor, offering a breakthrough solution to the global health challenge of excessive salt consumption. Paul Patsapong Chomchey, a graduate of Chulalongkorn University's Executive MBA Program, Class
- 김갑성 기자
- 2025-10-07 09:00
UEG Week 2025: Microplastics found to change gut microbiome in first human-sample study

BERLIN, Oct. 7, 2025 -- New research presented today at UEG Week 2025 shows that microplastics – plastic particles smaller than 5mm commonly found in the environment – can alter the human gut microbiome, with some changes resembling patterns linked to depression and colorectal cancer. This study, conducted within the framework of microONE, a pioneering COMET Module programme project led by CBmed research center in collaboration with international partners, is among the first to directly examine how different types of microplastics interact with the human gut microbiome. As part of micr
- 김갑성 기자
- 2025-10-07 06:01

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-10-19_SUN

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 19일 03시 20분